TP53 and lung cancer: Liquiritin, isoliquirigenin and isoliquiritin (Figure 5A) when applied in combination, against lung cancer cells, increased cytotoxic capacity and upregulated the p53 and p21 proteins, also downregulated the expression of MDM2, Bcl-2, p-Akt proteins through p53 dependent signaling pathway.